Register
Login:
Share:
Email Facebook Twitter


James Bevan on cybersecurity, banks and the housing market


Premaitha Share Chat (NIPT)



Share Price: 10.50Bid: 10.25Ask: 10.75Change: 0.00 (0.00%)No Movement on Premaitha
Spread: 0.50Spread as %: 4.88%Open: 10.50High: 10.50Low: 10.50Yesterday’s Close: 10.50


Share Discussion for Premaitha


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


notaflipper
Posts: 421
Observation
Opinion:No Opinion
Price:10.50
RE: Esperite
Tue 21:53
2016 Annual Report is published here:
http://www.esperite.com/?p=6119

Scroll right to the end where it talks about a going concern. They refer specifically to the L1 Capital Financing conditions which is currently uncertain to be met but which can be waived unconditionally. Does not look like the shareholders will have to await till July for further news. AGM was just a placeholder to buy some time
 
twix386
Posts: 2,516
Off Topic
Opinion:No Opinion
Price:10.50
The
Tue 15:05
Agenda etc can be downloaded from www.esperite.com
twix386
Posts: 2,516
Off Topic
Opinion:No Opinion
Price:10.50
Esperite
Tue 15:03
Esperite is convening an AGM for 4th July.

Should be interesting!
Sheephatch
Posts: 1,223
Off Topic
Opinion:No Opinion
Price:10.50
Telegraph article
Mon 20:41
New NHS test could lead to abortions of 'undesirable' babies, warn experts
13 Comments
A baby grips the finger of its mother
Women come under pressure to abort girls, the Nuffield Council on Bioethics claims CREDIT: DESIGN PICS INC/REX/SHUTTERSTOCK
Sarah Knapton, science editor
22 MAY 2017 • 1:04AM
A blood test which reveals the sex of a baby after nine weeks as well as identifying undesirable traits should be restricted to avoid parents aborting their babies for spurious reasons, a Government-backed think tank has said.

Non-invasive prenatal testing (NIPT) is a new screening tool which was designed to tell parents if their child could be suffering from Down’s Syndrome.

But the Nuffield Council on Bioethics has warned that unscrupulous clinics may use the test to ensure a mother will have a boy or certain genetic traits such as height or hair colour.

The warning comes amid fears that some doctors are unlawfully performing abortions purely on the basis of sex.

Professor Tom Shakespeare, chair of the body’s working group on NIPT, warned that the test could allow encourage ‘sex-selection tourists,’ from other countries who want to be sure they are having a boy.

“Abortions on the basis of sex appear to be rare in Britain. However, this could change with a new DNA testing method that allows the baby’s sex to be revealed to prospective parents much earlier that the standard 18-20 week scan,” he said.

ADVERTISING

“We know that some women are under strong pressure to give birth to boys, and may be subject to abuse if they give birth to a girl.

“If left unchecked, use of this technique to determine sex could lead to an increase in sex-selective abortions here, and to Britain becoming a destination for them.

"The test also allows whole genome sequencing which is a serious thing. People are already paying thousands for school fees so it is not unreasonable they would pay to find out if their child will have genetic traits that would allow them to perform well.

"We're not there quite yet, but we're not far off, and we are calling for a moratorium to be put in place now before we get there to stop this sort of thing happening."

A woman sitting on the ground holding a young baby girl.
The NIPT test can predict the sex of a baby CREDIT: MINT IMAGES
NIPT uses a blood sample taken from the placenta of pregnant woman and is seen as a major breakthrough in prenatal screening for a range of serious conditions because it negates the risk of miscarriage caused by conventional invasive tests.

From this year, the NHS will offer the test to expectant mothers to screen for Down’s, Patau’s and Edwards’ syndromes if doctors already fear their baby has a higher than average risk.

The test can also predict the sex of the baby, however, and the Nuffield Council says private doctors are selling it to couples without asking them to
bakky
Posts: 4,437
Off Topic
Opinion:No Opinion
Price:10.375
RE: Genoma appeal
Mon 12:04
Looks like their own auditors need some answers from the board before they will sign off accounts, not looking good for Esperite!!

Esperite N.V. (Euronext: ESP, the “Company” or “Esperite“) announces that additional time is needed for the Company to publish its Annual Report for the fiscal year ended 31 December 2016. This further delay is a consequence of the recently announced court ordered bankruptcy of Genoma S.A., a Swiss wholly-owned subsidiary of Esperite, and the subsequent appeal lodged by Genoma against the court order. The Company’s auditor, Ernst & Young Accountants LLP, has raised several technical questions regarding the bankruptcy and appeal proceedings, which must be addressed by the Company’s Board of Directors and its legal counsel in Switzerland before Ernst & Young can complete its audit procedures and audit of the Company’s Annual Report. Esperite continues to strive to publish its Annual Report and Q1 2017 Trading Update as promptly as practicable
bakky
Posts: 4,437
Off Topic
Opinion:No Opinion
Price:10.375
RE: Genoma appeal
Mon 10:16
Esperite getting even further away from their Eur 0.70 figure they need to maintain to secure funding. I can't see it getting anywhere near that figure as things stand so Esperite will go down the pan too it seems, or is it that simple?
Boyzee
Posts: 375
Off Topic
Opinion:No Opinion
Price:10.75
RE: Genoma appeal
Mon 07:51
Thanks Notaflipper ....interesting ...
notaflipper
Posts: 421
Off Topic
Opinion:No Opinion
Price:10.625
View Thread (2)
RE: Genoma appeal
Sun 22:38
I think one thing ppl are failing to understand is the conditions of the recent Espirite financing. in March
Espirite secured external financing of up to EUR 9 million investment which can reach EUR 13 million upon exercise of share subscription warrants

This included a private placement of EUR 1 million launched through the issuance of convertible notes with share subscription warrants attached. And a maximum additional potential financing of up to EUR 8 million through similar further private placements of convertible notes with share subscription warrants attached over the next 36 months, subject to fulfilment of certain conditions

Most importantly one of the conditions was that "the closing price and the daily volume weighted average price on each of the 5 preceding trading days shall be at least equal to EUR 0.70"

see point (viii) on page 5 of 7. This is the reason why the Dutch investors are worried about Espirite's survival as the L1 financing is now at risk...
http://www.esperite.com/wp-content/uploads/2017/03/08_03_2017_esperite_secures_external_financing.pdf

re EU commission...
Drif's made a good point...If Illumina or the now purchased Sequenom are found to be violating European competition rules, the European Commission could impose licensing terms as well as fines of up to 10 percent of each company's revenue.

The commission is investigating whether the creation of Illumina's and Sequenom's patent pool agreement in 2014 and its actions since then infringe articles 101 and 102 of EU competition law, which prohibit restrictive agreements and the abuse of a dominant position, respectively. The commission is also looking into Illumina's licensing practices and whether they raise competition law concerns. Also at the case management conference, the court ordered that AFTER the patent hearings in July 2017, it would consider Premaitha's competition law defense. At that point, the court said, it would have more certainty on the validity of the technical claims and on the investigation by the European Commission.
bakky
Posts: 4,437
Off Topic
Opinion:No Opinion
Price:10.625
RE: Genoma appeal
Sun 22:32
doesn't look good for Esperite, trying everything to conceal what is really going on,even saying that things are going on as normal...has nobody told him Genoma are bankrupt!! bloody idiot!
notaflipper
Posts: 421
Off Topic
Opinion:No Opinion
Price:10.625
View Thread (2)
RE: Genoma appeal
Sun 21:33
2 Dutch articles
Besides being the main source of independent information for the Dutch investor, the VEB is widely known for its collective redress (VEB actions) – lawsuits typically brought to obtain compensation for groups of aggrieved shareholders.
https://www.veb.net/media/3547/20170516-letter-to-esperite-concerning-genoma.pdf

AMSTERDAM (AFN) - Esperite has announced its postponement for the publication of its 2016 annual accounts and a trading update for the first months of this year. After a previous delay, it should have already appeared on Friday. A new date is not mentioned. That made the stem cell company listed in Amsterdam known this weekend.

In a brief statement, the company indicates that the new postponement is a consequence of the recently announced bankruptcy of subsidiary Genoma in Switzerland. Genoma was appealed against that decision. The accountant of Esperite, Ernst & Young, has a number of questions about the bankruptcy that must be answered first.

Topman Frédéric Amar said to the ANP on Friday that the absence of the publication had nothing to do with Genoma's bankruptcy. He did not want to go into accounting, but spoke of a "difficult and technical case". Amar was not available on Sunday for a response to the new postponement.

Esperite has previously released the annual report because the company and its accountant said, in their opinion, more time needed. External financing had to be processed in the books.

The share of Esperite was heavily under pressure at the stock exchange in Amsterdam on Friday, with an intermediate rate of around 30 percent. Esperite eventually closed 7 percent lower.

It is also remarkable that Esperite released a press release on Friday, via the company's usual means, ie by email and via the website. It stated that it was in Switzerland against bankruptcy. The new postponement was only brought to a fairly unobtrusive place on the website.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.